TP53 and neoplasm: Since intact p53 may reduce the sensitivity of tumor cells to selective PLK1 inhibition by suppressing the basal level of PLK1, cells with TP53 mutations may have a greater susceptibility to PLK1 inhibition, which was reported in a prior study 67.